Browse studies

Find your next paid study

29 recruiting studies matching your filters

HCMR Re-Imaging Study

This study aims to learn what might predict heart problems (like sudden death from a fast heart rhythm or heart failure) in people with a genetic condition cal…

Hypertrophic Cardiomyopathy (HCM)

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Christopher KramerNCT07054073

Observational

AVAVA MIRIA General Use

A general protocol to treat a variety of dermatologic conditions and collect patient feedback. Primary outcome is the collection and analysis of patient quest…

AcneAcne Scars - Mixed Atrophic and HypertrophicScars+3 more

Estimated

~$10 – $1,050

Actual pay is set by the research site.

AVAVA, Inc.NCT06868615

Coordination of Rare Diseases at Sanford

The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research. Indi…

Rare DisordersUndiagnosed DisordersDisorders of Unknown Prevalence+351 more

Phase 1

A Two-Part, Phase 1, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and WISPER Target Engagement of HTX-001 in Adult Healthy Participants (Part 1) and in Adult Participants With Nonobstructive Hypertrophic Cardiomyopathy (Part 2)

The purpose of this study is to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of HTX-001 in human adult participants.

Nonobstructive Hypertrophic Cardiomyopathy

Estimated

~$500 – $10,500

Actual pay is set by the research site.

Haya Therapeutics, Inc.NCT07867288

Phase 2

A Global Phase 2b, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy - FORTITUDE-HCM

FORTITUDE-HCM is a global, multicenter, double-blind, parallel-group, placebo-controlled Phase 2b study that will assess the efficacy and safety of ninerafaxst…

Non-obstructive Hypertrophic Cardiomyopathy

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Imbria Pharmaceuticals, Inc.NCT07023614